April 1st 2025
Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
American Academy of Pediatrics Landmark Obesity Guidelines Recommend Proactive, Aggressive Approach
January 9th 2023The comprehensive recommendations are the first in 15 years and focus on early evaluation and aggressive treatment that includes family support and accommodates social determinants of health.